Zobrazeno 1 - 10
of 57
pro vyhledávání: '"D R, Ferry"'
Autor:
David Ransom, Timothy J. Price, Val Gebski, D. R. Ferry, S. Gordon, Christos S. Karapetis, M. Fournier, Desmond Yip, R. J. Simes, Niall C. Tebbutt, Kate Wilson
Publikováno v:
Annals of Oncology. 25:117-121
Background Cardiac toxicity an uncommon but serious side-effect of some fluoropyrimides. Cardiac toxicity from raltitrexed is rarely reported. With this background, we initiated this study to investigate the incidence of cardiac events in patients wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1b297fc618e759ab79fd59061e4d402
https://doi.org/10.1093/annonc/mdt479
https://doi.org/10.1093/annonc/mdt479
Autor:
Kelly Handley, Bryan F. Warren, Z B Gray, Philip Quirke, Laura Magill, Dion Morton, Gina Brown, D. R. Ferry, F C Grp, Matthew T. Seymour, Richard Gray
3568 Background: Preoperative CT and radiotherapy are surprisingly more effective than postoperative treatment in rectal and other cancers, perhaps because micrometastases are more readily eradicat...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c5970d6bfce825a18c6ef7b5312ee82
https://ora.ox.ac.uk/objects/uuid:9e29a263-d947-4a4e-a82d-dea6ea30286d
https://ora.ox.ac.uk/objects/uuid:9e29a263-d947-4a4e-a82d-dea6ea30286d
Autor:
David J. Kerr, Jim Cassidy, Richard Poyner, Leonard W. Seymour, D. R. Ferry, Hilary Calvert, Ruth Duncan, Andreas G. Schätzlein, Stuart Hesslewood, Duncan I. Jodrell, Daniel Rea, Robert Blackie, Adele Robbins, Michael J. Lind, Maggie Whitlock, Donald Bissett, Sally Burtles, Christopher M Boivin, Chris Twelves
Phase I studies of [N-(2-hydroxypropyl)methacrylamide] (HPMA) copolymer-doxorubicin previously showed signs of activity coupled with 5-fold decreased anthracycline toxicity in chemotherapy-refractory patients. Here we report phase H studies using a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e00789a5e76ad68835ad6a6ec539a96
https://doi.org/10.3892/ijo_00000293
https://doi.org/10.3892/ijo_00000293
Cisplatin in the modern era : The backbone of first-line chemotherapy for non-small cell lung cancer
Autor:
Yvonne Summers, T Benepal, Daniel C. Christoph, Rohit Lal, Dean A. Fennell, Manjulika Das, D. R. Ferry, Jacques Cadranel, F Maxwell, Carla Visseren-Grul
The treatment of advanced non-small cell lung cancer (NSCLC) may be changing, but the cisplatin-based doublet remains the foundation of treatment for the majority of patients with advanced NSCLC. In this respect, changes in practice to various aspect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18a8b2ac68a313027b72501b70104dfa
https://www.ncbi.nlm.nih.gov/pubmed/26866673
https://www.ncbi.nlm.nih.gov/pubmed/26866673
Autor:
Sumitra Thongprasert, Chun-Ming Tsai, Sven Gogov, Fabrice Barlesi, Ronald B. Natale, Peter Langmuir, Michael Thomas, Jacqui Rowbottom, Glenwood D. Goss, Patrapim Sunpaweravong, F. Anthony Greco, Joyce Thompson, Robert C. Whorf, D. R. Ferry, Clive Mulatero
Publikováno v:
Journal of Clinical Oncology. 29:1059-1066
Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. This phase III study assessed the efficacy of vandetanib versus erlotinib in unselected patients with adv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::696f234048f7b67849d1690875f4626b
https://doi.org/10.1200/jco.2010.28.5981
https://doi.org/10.1200/jco.2010.28.5981
Autor:
Tim Maughan, David Smith, Gareth Griffiths, Jonathan A. Ledermann, D. R. Ferry, Richard Stephens, C. Topham, Roger D James, L.C. Thompson, Stephen J. Gwyther, A Meade, Stephen F Shepherd, Mahesh K. B. Parmar, Anthony Maraveyas, Matthew T. Seymour
Publikováno v:
The Lancet. 370:143-152
Summary Background In the non-curative setting, the sequence in which anticancer agents are used, singly or in combination, may be important if patients are to receive the maximum period of disease control with the minimum of adverse effects. We comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6687629e5ef973d14306d1ef95128177
https://doi.org/10.1016/s0140-6736(07)61087-3
https://doi.org/10.1016/s0140-6736(07)61087-3
Autor:
Sarah Pearson, Tina Gamble, D. R. Ferry, Lynnda Peachey, Haider Abbas, Richard A Hubner, Janusz Jankowski, Patrick Julier, Rachel Kerr, Asa Dahle-Smith, Joyce Thompson, Stephen Falk, Angel Garcia-Alonso, Russell D. Petty, Anirban Chatterjee, Susan J Dutton, Wasat Mansoor, Jane M Blazeby, D. Fyfe, Mina Davoudianfar, Mark Harrison
Publikováno v:
The Lancet. Oncology. 15(8)
Summary Background Evidence is scarce for the effectiveness of therapies for oesophageal cancer progressing after chemotherapy, and no randomised trials have been reported. We aimed to compare gefitinib with placebo in previously treated advanced oes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5289071bb8b72524a2cf9bb7ec290b9b
http://ora.ox.ac.uk/objects/uuid:19906f31-3e43-443f-8b17-12f92a865d95
http://ora.ox.ac.uk/objects/uuid:19906f31-3e43-443f-8b17-12f92a865d95
Publikováno v:
Scopus-Elsevier
Adenocarcinoma of the oesophagus is a systemic disease at presentation in the majority of patients. This article analyses the impact of preoperative chemotherapy on a cohort of 68 patients. From 1990 to 1996, 68 patients with potentially operable ade
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a20166330cbc261dd94699c9cb90a7ac
https://doi.org/10.1007/s001740170068
https://doi.org/10.1007/s001740170068
Publikováno v:
Annals of Oncology. 12:161-172
Hepatocellular carcinoma (HCC) is the sixth most common cancer of men and eleventh most common cancer of women world-wide. However, because almost every individual who develops liver cancer dies of the disease, HCC is the third most common cause of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::137785b5308737e8dc25ce9763698c2d
https://doi.org/10.1023/a:1008370324827
https://doi.org/10.1023/a:1008370324827
Autor:
D. R. Ferry, J. E. Cook, D. Anderson, E. Hodgkin, Leonard W. Seymour, Syed A. Hussain, David J. Kerr, Annie M. Young, Paul Mulholland
Publikováno v:
Annals of Oncology. 12:245-248
Summary Background: Quercetin is a naturally occurring flavonoid with many biological activities including inhibition of a number of tyrosine kinases. A phase I, dose-escalati on trial of quercetin defined the maximum tolerated dose (MTD) as 1700 mg/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50a7fa11077d6516e1a6a22b500a21ea
https://doi.org/10.1023/a:1008372017097
https://doi.org/10.1023/a:1008372017097